Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity

scientific article published on January 1987

Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1476-5381.1987.TB16833.X
P932PMC publication ID1917269
P698PubMed publication ID2880622
P5875ResearchGate publication ID20274880

P2093author name stringJ Casals-Stenzel
K H Weber
P2860cites workCharacterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864Q28264829
Present concepts on the mechanisms of platelet aggregationQ40302756
Background and present status of research on platelet-activating factor (PAF-acether).Q40312852
Interaction of benzodiazepines with mouse macrophagesQ41537156
Autoradiographic localization of "peripheral-type" benzodiazepine binding sites in the rat brain, heart and kidneyQ48531376
Benzodiazepine receptors on human blood plateletsQ51836725
Characterization of a peripheral-type benzodiazepine binding site on human circulating lymphocytes.Q51852159
Properties of [3H]diazepam binding sites on rat blood plateletsQ51872339
Properties of [3H] diazepam binding to rat peritoneal mast cellsQ51875358
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregationQ58831985
Selective antagonists of benzodiazepinesQ59057876
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesQ72144140
Platelet-Activating Factor-Induced Aggregation of Human Platelets Specifically Inhibited by TriazolobenzodiazepinesQ72594997
THE AGGREGATION OF BLOOD PLATELETSQ76530970
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)139-146
P577publication date1987-01-01
P1433published inBritish Journal of PharmacologyQ919631
P1476titleTriazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity
P478volume90

Reverse relations

cites work (P2860)
Q46682830Effect of WEB 2170 BS, platelet activating factor receptor inhibitor, in the guinea pig model of middle ear inflammation
Q35756578Effect of endothelium on basal and on stimulated accumulation and efflux of cyclic GMP in rat isolated aorta
Q38627145Hetrazepines as antagonists of platelet activating factor
Q67953472Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation
Q41906314Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells
Q35756710Intracellular platelet-activating factor regulates eicosanoid generation in guinea-pig resident peritoneal macrophages
Q35756479Limited interference of specific Paf antagonists with hyper-responsiveness to Paf itself of lungs from actively sensitized guinea-pigs
Q41662880Long time incubation of monocytic U 937 cells with LDL increases specific paf-acether binding and the cellular acetylhydrolase activity
Q39635714PAF antagonists. Their potential therapeutic role in asthma
Q40524595Platelet activating factor antagonists
Q37885574Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists
Q44472575Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia
Q35755135The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig
Q38247605The role of platelet activating factor in allergic inflammation
Q28768533The role of platelet activating factor in allergic respiratory disease
Q36471356Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: Present status
Q40490600Treatment of bronchospastic disorders in the 1990s. What does the future hold?